John H. Johnson
Savient Pharmaceuticals, Chief Executive Officer
John H. Johnson has more than two decades of executive and operational management experience in the biopharmaceutical and healthcare industries.
Mr. Johnson was appointed Senior Vice President and President, Global Oncology Business Unit, Eli Lilly and Company, effective November 1, 2009. Prior to this appointment, he served as Chief Executive Officer of ImClone Systems since August 2007 and was also a member of ImClone’s Board of Directors until the company became a wholly-owned subsidiary of Lilly in November 2008.
Prior to joining ImClone, Mr. Johnson served as Company Group Chairman of Johnson & Johnson’s Worldwide Biopharmaceuticals unit. In this executive role, he was responsible for the Johnson & Johnson Biotechnology, Immunology and Oncology commercial businesses, including Centocor, Inc., Ortho Biotech Products, L.P. and the Worldwide Strategic Marketing group.
Mr. Johnson began his healthcare career with Pfizer in 1983 where he held positions of increasing responsibility in sales and sales management. He joined Johnson & Johnson in 1988 to help lead their entry into the Anti-Infectives business. Mr. Johnson advanced through positions of increasing responsibility with Ortho-McNeil, including leading the commercial groups responsible for the development of sales, marketing and new product strategies of several of the company’s flagship brands, including LEVAQUIN®, ULTRAM® and TOPAMAX®. In 2000, he left Johnson & Johnson to assume the position of President and Chief Executive Officer for Parkstone Medical Information Systems. Mr. Johnson returned to Johnson & Johnson in 2002 as Worldwide Vice President, CNS/Psychiatry, for Johnson & Johnson Pharmaceuticals Group Strategic Marketing. He was appointed President of Ortho Biotech Products, L.P. in March 2003, and assumed responsibility for Ortho Biotech Canada in 2004. He held this position until being named Company Group Chairman in 2005.
Mr. Johnson received a B.S. degree from East Stroudsburg University of Pennsylvania. Currently, Mr. Johnson serves on the boards of BioNJ and Cempra Pharmaceuticals, Inc.
